SEBULSKY ALAN

SEC Form 4 insider trading activity

SEBULSKY ALAN has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Jun 16, 2026.

On the most recent filing, SEBULSKY ALAN is listed as Director at Parabilis Medicines, Inc. Inside the rolling window, SEBULSKY ALAN reported 3 open-market purchases totaling $724K in PBLS and no open-market sales. The largest disclosed transaction in the window is a purchase of 12,500 PBLS shares on Jun 11, 2026, worth $250K.

Companies traded

Other insiders at PBLS

Insider Buying

$724K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
PBLSPurchase$233KJun 16SEC ↗
PBLSPurchase$240KJun 16SEC ↗
PBLSPurchase$250KJun 15SEC ↗
Showing 1–3 of 3
1 / 1

Frequently asked questions

How many SEC Form 4 filings has SEBULSKY ALAN made?

SEBULSKY ALAN has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company since 2026.

Which companies does SEBULSKY ALAN trade?

SEBULSKY ALAN has filed SEC Form 4 disclosures for 1 company, including PBLS.

When was SEBULSKY ALAN's most recent SEC Form 4 filing?

SEBULSKY ALAN's most recent SEC Form 4 filing on Tracefour is dated Jun 16, 2026.

What is SEBULSKY ALAN's total buy and sell value in the current window?

Inside the rolling retention window, SEBULSKY ALAN bought $724K and sold $0 based on SEC Form 4 filings.

What was SEBULSKY ALAN's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 12,500 PBLS shares on 2026-06-11, worth $250K, per SEC Form 4 filings.